We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
The first wholesaler to offer insurance products for B2B and B2C firms in the Sharing Economy. Inlet aims provide insurance for assets that have been peer-to-peer rented for the short term, or for the provision of services such as letting properties online, as these markets are not currently covered by traditional insurances. Inlet generates revenue from commissions via insurance products at the point of sale and at policy renewal. Income in the form of interest payments is also earned from customers that choose to pay via direct debit on a monthly basis, as well as from fees applied to customers who wish to amend their policies.
days to go: Expired investment: £256,514
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
WorkClub converts under-used real estate into productive co-working areas and provides an affordable membership for remote workers across London. The company has 500+ members, 800+ guests and 25 WorkClub’s spaces in London. WorkClub has also secured many venues across the UK with Young's, Hippo Inns and more. Furthermore, it is listed as a ‘Top 10 startup to watch’ by TechRound, has 4.8* rating on TrustPilot and, acquired 30 businesses to offer discounted WorkClub memberships to members including ZipCar, PureGym. The company will use the funds to develop WorkClub’s technology and to expand its offering into other key UK cities.
days to go: Expired investment: £342,820
KindLink are a social network for donors and charities so donors are able to make a donation to their favourite charity and help them help other people. Donors are able to see the impact of the donations they are making by following the progress of the charity and updates for the project donated to. KindLink establishes a direct connection between donor and beneficiary to create a close and community-like feel.
days to go: Expired investment: £25,045
Business Finance Market (BFM) is a financial technology platform that stimulates the market towards Small and Medium Enterprises (SMEs) lending via data in the UK. BFM claims that SMEs are gradually being excluded from mainstream banking. The company cites that in 1988, 40% of all bank lending went to SMEs. BFM points out that lending today is closer to 4% with an estimated £22 billion funding gap to the 5.9 million UK SMEs. BFM asserts that almost 90% of SME loan applications are stuck due to a lack of choice and transparency when it comes to securing finance. BFM aspires to solve this dilemma. It states that its technology allows SMEs to experience quicker finance decisions based on true addressable market access and allows lenders and intermediaries access to its platform to help manage the end-to-end application process, improve deal flow, and deliver faster credit decisions. BFM intends to exit via a trade sale within the financial sector.
days to go: Expired investment: Withheld
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.

Pitch Rated

30%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph